• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AmacaThera raises $10.3M in oversubscribed Series A

February 22, 2021 By Sean Whooley

AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round.

Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according to a news release.

“The platform technology that we developed at AmacaThera has demonstrated potential in numerous disease indications with the delivery of proteins, antibodies, cells, and small molecules,” AmacaThera chief science officer Molly Shoichet said in the release. “We are thrilled to have the capital to advance our lead candidate to the clinic and strengthen our pipeline with new innovations.”

Toronto-based AmacaThera’s lead product, AMT-143, is being developed to treat post-surgical pain to materially reduce and potentially prevent the need for opioid-based pain relief, instead offering a single injection of the therapeutic to be administered at the time of surgery.

The company develops proprietary hydrogels to enable local, sustained release of small-molecule drugs, biotherapeutics and cells.

“We are excited to welcome our new investors and are grateful to the continued support of our existing investors,” AmacaThera CEO & co-founder Michael Cooke said. “We look forward to accelerating our clinical trials and expanding our pipeline of potential product offerings. We are focused on advancing our lead asset through the clinic and developing partners with whom we can leverage our injectable sustained release platform.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Hydrogels, Pain Management, Pharmaceuticals, Surgical Tagged With: AmacaThera

IN CASE YOU MISSED IT

  • BriaCell Therapeutics closes $25M offering
  • ICU Medical dips despite Street-beating Q4
  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS